mtm

CMS Allows Absolute Biosimilar Substitution In Part D Medicare Part D plans can now immediately substitute all FDA-approved biosimilars even if they are not deemed interchangeable by the drug approval agency, under the 2025 Medicare Advantage (MA) and Part D rule finalized by the Centers for Medicare and Medicaid Servies (CMS). Interchangeability is an extra step that drug makers take to substitute for brand biologics. The new rule will allow Part D plans to treat formulary substitutions of any biosimilars as maintenance changes as was allowed earlier just for interchangeables. The Biden administration has pushed for biosimilar adoption in many ways and this is yet another. This should begin to mean lower biologic costs for Medicare members. (Article may require a subscription.) #biosimilars #drugpricing #medicareadvantage #partd #medicare Link to Article CMS Changes MTM Criteria, Including Adding HIV/AIDs As Core Disease State The Centers for Medicare and Medicaid Services (CMS) finalized